Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings

May 23 2018

• By Malcolm Spicer

FDAEntrance_1200x675

Related Content

DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

Oct 14 2016

Kratom: All Questions On Pre-DSHEA Ingredient Evidence In One Package

Oct 16 2017

FDA's Opioid Label For Kratom Called Misbranding By Marketers

Feb 07 2018

Las Vegas Kratom Marketer Rolls Dice On FDA's Mandatory Recall Authority

Apr 03 2018

AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement

Apr 30 2018

Additional Topics

United States Dietary Supplements Safety FDA Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window